FOSUN PHARMA
復星医药

**上海復星醫藥（集團）股份有限公司**

# Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

## OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***
**Chen Yuqing**
*Chairman*

Shanghai, the PRC
24 September 2025

*As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Pan Donghui and Mr. Wu Yifang; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.*

* *for identification purposes only*

# Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
# Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

**The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.**

## I. Overview

Recently, the drug registration application of Brexucabtagene Autoleucel Injection (project no.: FKC889, registration category of application: Therapeutic biological product Category 3.2; hereinafter the "**Product**") of Fosun Kairos (Shanghai) Biological Technology Co., Ltd.* (復星凱瑞(上海)生物科技有限公司, "**Fosun Kairos**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the "**Company**"), was accepted by the National Medical Products Administration. The declared indication for this application is for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

## II. General Information and Research Progress of the Product

The Product is a CD19-targeted CAR-T cell therapy developed and locally produced in China (including Hong Kong and Macau) by Fosun Kairos through technology transfer and authorization from Kite Pharma, Inc. (a subsidiary of Gilead Sciences, Inc.), based on Tecartus. Tecartus received approval for marketing in the United States and Europe in July and December 2020, respectively.

As of the date of this announcement (i.e., 24 September 2025, the same applies below), another indication of the Product (i.e., for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL) after two or more lines of systemic therapy) is currently at the bridging clinical trial stage in China (excluding Hong Kong, Macau, and Taiwan, the same applies below).

As of August 2025, the Group (i.e., the Company and its subsidiaries/units, the same applies below) has invested approximately RMB183 million (unaudited) in total in the research and development of the Product at current stage.

As of the date of this announcement, several CAR-T cell therapy products, including Yi Kai Da (Axicabtagene Ciloleucel Injection) of Fosun Kairos, have been approved for marketing in China. Due to factors such as the coverage of sales channels in databases, the overall market situation cannot be accurately queried through public databases.

**III. Risk Warning**

The Product is subject to, among others, the passing of the GMP compliance inspection and the drug registration approval before commercial production. This acceptance of the drug registration application will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of the pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

24 September 2025

* *For identification purposes only*